Tillmann Michels

Years Active: 2020-2021
Publications (10 Years): 2

iOmx Therapeutics AG

German Cancer Research Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

iOmx Therapeutics AG Apr 01 2018

Germany

Team Leader :: Target Discovery

University Hospital Regensburg Sep 01 2015 - Mar 31 2018

Germany

Group leader :: Regensburg Center for Interventional Immunology

Education History

German Cancer Research Center Jun 01 2012 - Dec 14 2017

Germany

PHD :: Translational Immunology

Publications

Maria Xydia, Raheleh Rahbari, Eliana Ruggiero, Iain Macaulay, Maxime Tarabichi, Robert Lohmayer, Stefan Wilkening, Tillmann Michels, Daniel Brown, Sebastiaan Vanuytven, Svetlana Mastitskaya, Sean Laidlaw, Niels Grabe, Maria Pritsch, Raffaele Fronza, Klaus Hexel, Steffen Schmitt, Michael Müller-Steinhardt, Niels Halama, Christoph Domschke, Manfred Schmidt, Christof von Kalle, Florian Schütz, Thierry Voet, Philipp Beckhove
Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients. Nature communications 12 (1) (2021)
Valentina Volpin, Tillmann Michels, Antonio Sorrentino, Ayse N Menevse, Gertrud Knoll, Madlen Ditz, Vladimir M Milenkovic, Chih-Yeh Chen, Anchana Rathinasamy, Klaus Georg Griewank, Michael Boutros, Sebastian Haferkamp, Mark Berneburg, Christian H Wetzel, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Martin Ehrenschwender, Mathias Witzens-Harig, Arpad Szoor, Gyorgy Vereb, Nisit Khandelwal, Philipp Beckhove
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment. Cancer immunology research 8 (9) (2020)

Tillmann Michels.css-eqlu8i{font-size:small;padding-left:4px;}